Oncolytics Biotech (ONCY) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 47.4% versus a loss of 57.8%. Zhengye Biotechnology is the larger company by market cap ($66.3 million vs $65.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCY | ZYBT |
|---|---|---|
| Share price | $0.4981 | $1.40 |
| Market cap | $65.31M | $66.35M |
| 1-day change | -9.04% | -6.67% |
| YTD return | -42.75% | +21.74% |
| 1-year return | -57.79% | -47.37% |
| 5-year return | -77.76% | — |
| EPS (TTM) | $-0.35 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.64M |
| Revenue growth (YoY) | — | -34.83% |
| Net income (latest FY) | $-28.76M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | — | -60.60% |
| Net margin | — | -59.99% |
| 52-week high | $1.32 | $8.01 |
| 52-week low | $0.44 | $0.616 |
| Distance from 52-week high | -62.27% | -82.52% |
| Analyst consensus | buy | — |
| Avg. price target upside | +733.17% | — |
| Average volume | 1.09M | 5.64M |
| Shares outstanding | 131.12M | 47.39M |
| Employees | 29 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed ONCY by 10.4 percentage points over the past year.
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
ONCY vs ZYBT FAQ
Which is bigger, Oncolytics Biotech or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $66.35M compared with $65.31M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, ONCY or ZYBT?
ZYBT returned -47.37% over the past 12 months, compared with -57.79% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Oncolytics Biotech and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.